A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin

Radiotherapy and Oncology

Volumn 103, Issue 3, 2012, Pages 394-401

  Reichert, Sebastian ^a   Reinboldt, Vera ^a   Hehlgans, Stephanie ^a   Efferth, Thomas ^b   Rödel, Claus ^a   Rödel, Franz ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Artesunate; Glioblastoma; Radiosensitization; Survivin

Indexed keywords

APOPTOSIS INHIBITOR; ARTESUNATE; CASPASE 3; CASPASE 7; GREEN FLUORESCENT PROTEIN; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL COUNT; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENIC ASSAY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOFLUOROMETRY; DNA REPAIR; DOSE RESPONSE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TREATMENT RESPONSE; WESTERN BLOTTING;

APOPTOSIS; ARTEMISININS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM PROTEINS; RADIATION-SENSITIZING AGENTS;

EID: 84861797048     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.03.018     Document Type: Article

References (48)

1. C. Adamson, O.O. Kanu, and A.I. Mehta Glioblastoma multiforme: a review of where we have been and where we are going Expert Opin Investig Drugs 18 2009 1061 1083
2. D.C. Altieri Survivin and IAP proteins in cell-death mechanisms Biochem J 430 2010 199 205
3. D.C. Altieri Survivin, cancer networks and pathway-directed drug discovery Nat Rev Cancer 8 2008 61 70
4. L. Anfosso, T. Efferth, A. Albini, and U. Pfeffer Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins Pharmacogenomics J 6 2006 269 278
5. F.F. Angileri, M. Aguennouz, and A. Conti Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas Cancer 112 2008 2258 2266
6. B. Bachmeier, I. Fichtner, P.H. Killian, E. Kronski, U. Pfeffer, and T. Efferth Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells PLoS One 6 2011 e20550
7. S. Bao, Q. Wu, and R.E. McLendon Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
8. N. Berdelle, T. Nikolova, S. Quiros, T. Efferth, and B. Kaina Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks and the ATM/ATR damage response in cancer cells Mol Cancer Ther 10 2011 2224 2233
9. T.G. Berger, D. Dieckmann, and T. Efferth Artesunate in the treatment of metastatic uveal melanoma - first experiences Oncol Rep 14 2005 1599 1603
10. P.A. Berman, and P.A. Adams Artemisinin enhances heme-catalysed oxidation of lipid membranes Free Radic Biol Med 22 1997 1283 1288
11. G. Capalbo, K. Dittmann, and C. Weiss Radiation-induced survivin nuclear accumulation is linked to DNA damage repair Int J Radiat Oncol Biol Phys 77 2010 226 234
12. A. Chakravarti, G.G. Zhai, and M. Zhang Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms Oncogene 23 2004 7494 7506
13. H. Chen, B. Sun, and S. Wang Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB J Cancer Res Clin Oncol 136 2010 897 903
14. R. Dell'Eva, U. Pfeffer, and R. Vene Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate Biochem Pharmacol 68 2004 2359 2366
15. T. Efferth Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells Curr Drug Targets 7 2006 407 421
16. T. Efferth Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside Planta Med 73 2007 299 309
17. T. Efferth, H. Dunstan, A. Sauerbrey, H. Miyachi, and C.R. Chitambar The anti-malarial artesunate is also active against cancer Int J Oncol 18 2001 767 773
18. T. Efferth, M. Giaisi, A. Merling, P.H. Krammer, and M. Li-Weber Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells PLoS One 2 2007 e693
19. T. Efferth, and F. Oesch Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines Biochem Pharmacol 68 2004 3 10
20. T. Efferth, A. Sauerbrey, and A. Olbrich Molecular modes of action of artesunate in tumor cell lines Mol Pharmacol 64 2003 382 394
21. J. Gerstein, K. Franz, and J.P. Steinbach Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma Radiother Oncol 97 2010 382 386
22. M. Gyrd-Hansen, and P. Meier IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer Nat Rev Cancer 10 2010 561 574
23. E.J. Hall, M. Astor, and J. Bedford Basic radiobiology Am J Clin Oncol 11 1988 220 252
24. A. Hamacher-Brady, H.A. Stein, and S. Turschner Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production J Biol Chem 286 2011 6587 6601
25. J. Hou, D. Wang, R. Zhang, and H. Wang Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action Clin Cancer Res 14 2008 5519 5530
26. T. Iwasa, I. Okamoto, and M. Suzuki Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines Clin Cancer Res 14 2008 6496 6504
27. R.K. Kanwar, C.H. Cheung, J.Y. Chang, and J.R. Kanwar Recent advances in anti-survivin treatments for cancer Curr Med Chem 17 2010 1509 1515
28. S.J. Kim, M.S. Kim, and J.W. Lee Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro J Cancer Res Clin Oncol 132 2006 129 135
29. D.L. Klayman Qinghaosu (artemisinin): an antimalarial drug from China Science 228 1985 1049 1055
30. H. Lai, and N.P. Singh Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat Cancer Lett 231 2006 43 48
31. P.C. Li, E. Lam, W.P. Roos, M.Z. Zdzienicka, B. Kaina, and T. Efferth Artesunate derived from traditional Chinese medicine induces DNA damage and repair Cancer Res 68 2008 4347 4351
32. S.R. Meshnick, Y.Z. Yang, V. Lima, F. Kuypers, S. Kamchonwongpaisan, and Y. Yuthavong Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu) Antimicrob Agents Chemother 37 1993 1108 1114
33. M. Michaelis, M.C. Kleinschmidt, and S. Barth Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines Biochem Pharmacol 79 2010 130 136
34. R.B. Mikkelsen, and P. Wardman Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms Oncogene 22 2003 5734 5754
35. G. Minniti, D. Amelio, and M. Amichetti Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide Radiother Oncol 97 2010 377 381
36. J.C. Moore, H. Lai, and J.R. Li Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat Cancer Lett 98 1995 83 87
37. S. Reichert, C. Rödel, and J. Mirsch Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma Radiother Oncol 2011
38. F. Rödel, B. Frey, W. Leitmann, G. Capalbo, C. Weiss, and C. Rödel Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models Int J Radiat Oncol Biol Phys 71 2008 247 255
39. F. Rödel, J. Hoffmann, and L. Distel Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer Cancer Res 65 2005 4881 4887
40. F. Rödel, S. Reichert, and T. Sprenger The role of survivin for radiation oncology: moving beyond apoptosis inhibition Curr Med Chem 18 2011 191 199
41. P.J. Rosenthal Artesunate for the treatment of severe falciparum malaria N Engl J Med 358 2008 1829 1836
42. N.P. Singh, and V.K. Panwar Case report of a pituitary macroadenoma treated with artemether Integr Cancer Ther 5 2006 391 394
43. O. Thanaketpaisarn, P. Waiwut, H. Sakurai, and I. Saiki Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-kappaB and PI3K/Akt signaling pathways Int J Oncol 39 2011 279 285
44. L. Tracey, A. Perez-Rosado, and M.J. Artiga Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively J Pathol 206 2005 123 134
45. M.A. van Agtmael, T.A. van Eggelte, and C.J. Boxtel Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication Trends Pharmacol Sci 20 1999 199 205
46. Q. Xu, Z.X. Li, and H.Q. Peng Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo J Zhejiang Univ Sci B 12 2011 247 255
47. M. Youns, T. Efferth, J. Reichling, K. Fellenberg, A. Bauer, and J.D. Hoheisel Gene expression profiling identifies novel key players involved in the cytotoxic effect of artesunate on pancreatic cancer cells Biochem Pharmacol 78 2009 273 283
48. Z.Y. Zhang, S.Q. Yu, and L.Y. Miao Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial Zhong Xi Yi Jie He Xue Bao 6 2008 134 138